Logo image of VXL.CA

VAXIL BIO LTD (VXL.CA) Stock Fundamental Analysis

Canada - TSX-V:VXL - CA92243L2066 - Common Stock

0.19 CAD
0 (0%)
Last: 10/21/2025, 7:00:00 PM
Fundamental Rating

3

VXL gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 21 industry peers in the Biotechnology industry. While VXL has a great health rating, there are worries on its profitability. VXL does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year VXL has reported negative net income.
In the past year VXL has reported a negative cash flow from operations.
In the past 5 years VXL always reported negative net income.
In the past 5 years VXL always reported negative operating cash flow.
VXL.CA Yearly Net Income VS EBIT VS OCF VS FCFVXL.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -1M -2M -3M -4M

1.2 Ratios

VXL's Return On Assets of -14.20% is amongst the best of the industry. VXL outperforms 85.71% of its industry peers.
VXL's Return On Equity of -14.33% is amongst the best of the industry. VXL outperforms 85.71% of its industry peers.
Industry RankSector Rank
ROA -14.2%
ROE -14.33%
ROIC N/A
ROA(3y)-29.4%
ROA(5y)-42.62%
ROE(3y)-34.93%
ROE(5y)-66.34%
ROIC(3y)N/A
ROIC(5y)N/A
VXL.CA Yearly ROA, ROE, ROICVXL.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 -400 -600

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for VXL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VXL.CA Yearly Profit, Operating, Gross MarginsVXL.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

9

2. Health

2.1 Basic Checks

VXL has about the same amout of shares outstanding than it did 1 year ago.
VXL has less shares outstanding than it did 5 years ago.
There is no outstanding debt for VXL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
VXL.CA Yearly Shares OutstandingVXL.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
VXL.CA Yearly Total Debt VS Total AssetsVXL.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M 2M

2.2 Solvency

VXL has an Altman-Z score of 21.44. This indicates that VXL is financially healthy and has little risk of bankruptcy at the moment.
VXL has a Altman-Z score of 21.44. This is amongst the best in the industry. VXL outperforms 95.24% of its industry peers.
There is no outstanding debt for VXL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 21.44
ROIC/WACCN/A
WACCN/A
VXL.CA Yearly LT Debt VS Equity VS FCFVXL.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500K -500K 1M -1M 1.5M

2.3 Liquidity

A Current Ratio of 104.17 indicates that VXL has no problem at all paying its short term obligations.
The Current ratio of VXL (104.17) is better than 100.00% of its industry peers.
A Quick Ratio of 104.17 indicates that VXL has no problem at all paying its short term obligations.
The Quick ratio of VXL (104.17) is better than 100.00% of its industry peers.
Industry RankSector Rank
Current Ratio 104.17
Quick Ratio 104.17
VXL.CA Yearly Current Assets VS Current LiabilitesVXL.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M 2M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for VXL have decreased strongly by -109.84% in the last year.
EPS 1Y (TTM)-109.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%173.18%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for VXL. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VXL.CA Price Earnings VS Forward Price EarningsVXL.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VXL.CA Per share dataVXL.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 0.2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for VXL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VAXIL BIO LTD

TSX-V:VXL (10/21/2025, 7:00:00 PM)

0.19

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-24 2025-04-24
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners8.16%
Ins Owner ChangeN/A
Market Cap520.60K
Revenue(TTM)N/A
Net Income(TTM)-99000
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.75
P/tB 0.75
EV/EBITDA N/A
EPS(TTM)-0.04
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.09
FCFYN/A
OCF(TTM)-0.09
OCFYN/A
SpS0
BVpS0.25
TBVpS0.25
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -14.2%
ROE -14.33%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-29.4%
ROA(5y)-42.62%
ROE(3y)-34.93%
ROE(5y)-66.34%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 104.17
Quick Ratio 104.17
Altman-Z 21.44
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-109.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%173.18%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-83.49%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y69.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y69.18%
OCF growth 3YN/A
OCF growth 5YN/A

VAXIL BIO LTD / VXL.CA FAQ

What is the ChartMill fundamental rating of VAXIL BIO LTD (VXL.CA) stock?

ChartMill assigns a fundamental rating of 3 / 10 to VXL.CA.


What is the valuation status of VAXIL BIO LTD (VXL.CA) stock?

ChartMill assigns a valuation rating of 0 / 10 to VAXIL BIO LTD (VXL.CA). This can be considered as Overvalued.


How profitable is VAXIL BIO LTD (VXL.CA) stock?

VAXIL BIO LTD (VXL.CA) has a profitability rating of 2 / 10.


Can you provide the financial health for VXL stock?

The financial health rating of VAXIL BIO LTD (VXL.CA) is 9 / 10.